An analysis of buprenorphine distribution patterns among pharmacies and hospitals in the United States from 2019-2023. DOI Creative Commons

Maria Gikoska,

Anna K. Florio,

Andrew D. George

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 4, 2024

Abstract Background Opioid Use Disorder (OUD) is a debilitating condition characterized by the overuse of prescription opioid medications and development physical and/or psychological dependence. Consequences this include chronic impairment, distress, later life-altering health conditions such as overdose, all which have been highlighted prominence OUD in United States recent years. Buprenorphine standard treatment commonly used for pain management. Understanding changes distribution patterns across US vital continuing to improve outcomes patients. Methods This study analyzed buprenorphine among pharmacies hospitals from 2019-2023 determine temporal identify state level disparities. The Drug Enforcement Administrations’ Automated Reports Consolidated Ordering System (ARCOS), Census Bureau Population Estimates databases, mortality rates (CDC WONDER) were analyzed. Data corrected population 2021-2022 2022-2023 through examining percent milligrams per 100 at national level. Results year-to-year change has remained positive but changed 12.2% increase 2019-2020 four every year 2020-2023. From 2021-2022, there was +4.9% total grams distributed 95% CI [-5.1, 14.9], with District Columbia, South Dakota, Nebraska outside CI. Distribution increased 10.2% [-32.3, 52.7] during Hawaii, New Hampshire Delaware being 2022-2023, an +5.7% [-3.5, 14.9] pharmacy distribution, states including Washington, Rhode Island Kansas remaining Hospital decreased twenty between eighteen 2022-2023. Changes data showed no associations trends those Conclusion Following increases COVID pandemic, consistent continued year-over-year most country overall both hospitals. Some (e.g. Island, Georgia, Washington D.C.) not followed pattern. Notably, Hawaii went negative hospital timeframe may offer opportunities analyze more specific impacts on populations their associated OUD.

Language: Английский

Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research DOI
Ali Cheetham,

Elizabeth Grist,

Suzanne Nielsen

et al.

Current Opinion in Psychiatry, Journal Year: 2024, Volume and Issue: 37(4), P. 251 - 257

Published: April 29, 2024

Collaborative models of care where pharmacists work alongside physicians have been developed for a range physical health conditions, with benefits including improved patient outcomes and increased access to ongoing care. Opioid agonist treatment (methadone buprenorphine) is clinically effective cost-effective opioid use disorder that under-utilized in many countries due shortage prescribers. In recent years, there has interest the development collaborative utilize overcome barriers treatment. this article, we present narrative review synthesise rapidly developing area.

Language: Английский

Citations

5
An analysis of buprenorphine distribution patterns among pharmacies and hospitals in the United States from 2019-2023. DOI Creative Commons

Maria Gikoska,

Anna K. Florio,

Andrew D. George

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 4, 2024

Abstract Background Opioid Use Disorder (OUD) is a debilitating condition characterized by the overuse of prescription opioid medications and development physical and/or psychological dependence. Consequences this include chronic impairment, distress, later life-altering health conditions such as overdose, all which have been highlighted prominence OUD in United States recent years. Buprenorphine standard treatment commonly used for pain management. Understanding changes distribution patterns across US vital continuing to improve outcomes patients. Methods This study analyzed buprenorphine among pharmacies hospitals from 2019-2023 determine temporal identify state level disparities. The Drug Enforcement Administrations’ Automated Reports Consolidated Ordering System (ARCOS), Census Bureau Population Estimates databases, mortality rates (CDC WONDER) were analyzed. Data corrected population 2021-2022 2022-2023 through examining percent milligrams per 100 at national level. Results year-to-year change has remained positive but changed 12.2% increase 2019-2020 four every year 2020-2023. From 2021-2022, there was +4.9% total grams distributed 95% CI [-5.1, 14.9], with District Columbia, South Dakota, Nebraska outside CI. Distribution increased 10.2% [-32.3, 52.7] during Hawaii, New Hampshire Delaware being 2022-2023, an +5.7% [-3.5, 14.9] pharmacy distribution, states including Washington, Rhode Island Kansas remaining Hospital decreased twenty between eighteen 2022-2023. Changes data showed no associations trends those Conclusion Following increases COVID pandemic, consistent continued year-over-year most country overall both hospitals. Some (e.g. Island, Georgia, Washington D.C.) not followed pattern. Notably, Hawaii went negative hospital timeframe may offer opportunities analyze more specific impacts on populations their associated OUD.

Language: Английский

Citations

0